The role of monetary policy in managing the euro - dollar exchange rate

The US Federal Reserve’s new relaxed monetary policy (the so-called quantitative easing) has triggered controversy among economists and policy makers about its effectiveness. This paper investigates the role of monetary policy in managing the euro – dollar exchange rate via alternative cointegration tests and impulse response functions. It is found that monetary fundamentals have neither long- nor short-run impact on the exchange rate. This implies that the Fed’s quantitative easing schemes are unlikely to have any significant impact on the euro – dollar rate.Exchange rates; Monetary model; Cointegration; Impulse response functions

The role of monetary policy in managing the euro - dollar exchange rate

The US Federal Reserve’s new relaxed monetary policy (the so-called quantitative easing) has triggered controversy among economists and policy makers about its effectiveness. This paper investigates the role of monetary policy in managing the euro – dollar exchange rate via alternative cointegration tests and impulse response functions. It is found that monetary fundamentals have neither long- nor short-run impact on the exchange rate. This implies that the Fed’s quantitative easing schemes are unlikely to have any significant impact on the euro – dollar rate

The role of monetary policy in managing the euro - dollar exchange rate

The US Federal Reserve’s new relaxed monetary policy (the so-called quantitative easing) has triggered controversy among economists and policy makers about its effectiveness. This paper investigates the role of monetary policy in managing the euro – dollar exchange rate via alternative cointegration tests and impulse response functions. It is found that monetary fundamentals have neither long- nor short-run impact on the exchange rate. This implies that the Fed’s quantitative easing schemes are unlikely to have any significant impact on the euro – dollar rate

High Expression Levels of the Genes cyclin-A2 and glucocorticoid receptor Are Associated with High-Quality Embryos in Gilthead Sea Bream (Sparus aurata L.)

Identifying early egg-quality predictors is a major challenge in finfish hatcheries, and relevant research is now focused on the development of molecular markers. In our study, we examined whether fertilization rates and early morphological abnormalities in sea bream egg batches of high (HQ) and low quality (LQ) are associated with mRNA levels of cathepsin D, cathepsin Z, cyclin-A2, and glucocorticoid receptor. Additionally, we examined whether these early quality descriptors were associated with the development of skeletal abnormalities during the larval period. HQ egg batches were characterized by significantly higher rates of normal embryos (95.8 ± 2.3%) and lower rates of unfertilized (2.8 ± 1.0%) and abnormal eggs (1.3 ± 1.4%), compared to LQ (84.2 ± 0.8% normal embryos, 12.3 ± 12.3 unfertilized eggs, and 3.5 ± 1.4% abnormal eggs) (p < 0.05, Mann–Whitney U test). Relative expression of cyclin-A2 and glucocorticoid receptor was found to be significantly higher in HQ embryos compared to those of LQ (respectively, p < 0.01 and p < 0.05, Mann–Whitney U test). No statistically significant differences were observed in the mRNA transcripts of cathepsin D and cathepsin Z (p > 0.05, Mann–Whitney U test). Differences in the rate of skeletal abnormalities between the two quality groups of larvae were not significant (p > 0.05, G-test), indicating that cyclin-A2 and glucocorticoid receptor may serve as reliable molecular markers for early prediction of fish egg quality but not for later larval stages

Clinical implementation of preemptive pharmacogenomics in psychiatryResearch in context

Summary: Background: Pharmacogenomics (PGx) holds promise to revolutionize modern healthcare. Although there are several prospective clinical studies in oncology and cardiology, demonstrating a beneficial effect of PGx-guided treatment in reducing adverse drug reactions, there are very few such studies in psychiatry, none of which spans across all main psychiatric indications, namely schizophrenia, major depressive disorder and bipolar disorder. In this study we aim to investigate the clinical effectiveness of PGx-guided treatment (occurrence of adverse drug reactions, hospitalisations and re-admissions, polypharmacy) and perform a cost analysis of the intervention. Methods: We report our findings from a multicenter, large-scale, prospective study of pre-emptive genome-guided treatment named as PREemptive Pharmacogenomic testing for preventing Adverse drug REactions (PREPARE) in a large cohort of psychiatric patients (n = 1076) suffering from schizophrenia, major depressive disorder and bipolar disorder. Findings: We show that patients with an actionable phenotype belonging to the PGx-guided arm (n = 25) present with 34.1% less adverse drug reactions compared to patients belonging to the control arm (n = 36), 41.2% less hospitalisations (n = 110 in the PGx-guided arm versus n = 187 in the control arm) and 40.5% less re-admissions (n = 19 in the PGx-guided arm versus n = 32 in the control arm), less duration of initial hospitalisations (n = 3305 total days of hospitalisation in the PGx-guided arm from 110 patients, versus n = 6517 in the control arm from 187 patients) and duration of hospitalisation upon readmission (n = 579 total days of hospitalisation upon readmission in the PGx-guided arm, derived from 19 patients, versus n = 928 in the control arm, from 32 patients respectively). It was also shown that in the vast majority of the cases, there was less drug dose administrated per drug in the PGx-guided arm compared to the control arm and less polypharmacy (n = 124 patients prescribed with at least 4 psychiatric drugs in the PGx-guided arm versus n = 143 in the control arm) and smaller average number of co-administered psychiatric drugs (2.19 in the PGx-guided arm versus 2.48 in the control arm. Furthermore, less deaths were reported in the PGx-guided arm (n = 1) compared with the control arm (n = 9). Most importantly, we observed a 48.5% reduction of treatment costs in the PGx-guided arm with a reciprocal slight increase of the quality of life of patients suffering from major depressive disorder (0.935 versus 0.925 QALYs in the PGx-guided and control arm, respectively). Interpretation: While only a small proportion (∼25%) of the entire study sample had an actionable genotype, PGx-guided treatment can have a beneficial effect in psychiatric patients with a reciprocal reduction of treatment costs. Although some of these findings did not remain significant when all patients were considered, our data indicate that genome-guided psychiatric treatment may be successfully integrated in mainstream healthcare. Funding: European Union Horizon 2020